Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sarah Pellegrino, Senior Vice President, Investor Relations, and Corporate Communications. Please go ahead. Thank you, operator. Good afternoon, and thank you for joining the Iovance conference call and webcast to discuss our second quarter and first half 2025 financial results, as well as recent updates. Dr. Fred Vose, our interim chief executive officer and president, will provide an introduction and brief overview of our key financial results, including revenue and revenue guidance, operating expenses, and our strategic restructuring. Dan Kirby, Chief Commercial Officer, will discuss product revenue and commercial and regulatory updates for mTAGI. Dr. Igor Belinsky, our Chief Operating Officer, will provide a manufacturing update. And Dr. Frederick Finkenstein, our Chief Medical Officer, will summarize our priority pipeline program. Additional members of our leadership team, including Dr. Raj Puri, our Chief Regulatory Officer, and Dr. Brian Gassman, our Executive Vice President of Medical Affairs, will be available for the Q&A session. In addition, our new Chief Financial Officer, Coraline Roche, is joining today's call. Earlier this afternoon, we issued a press release that is available on our corporate website at iovance.com. Before we start, I would like to remind everyone that statements made during this conference call will include forwa...